Revenue
3.37 million USD
2019 Q3 · USD
Exact inputs and evidence
- Revenue: 3373000 USD Source
Fundies. English
Dova Pharmaceuticals Inc.
EDGAR13 filing records in this dataset, filed from 2017-06-02 to 2019-11-12. Reported financial figures are available; chart coverage varies by period.
Latest quarter
Operating margin
-612.66%
2019 Q3 · %
Operating cash flow
-19.4 million USD
2019 Q3 · USD
Free cash flow
-19.7 million USD
2019 Q3 · USD
- Cash and cash equivalents
- 68.4 million USD Source
Exact value
68400000 USD
- Long-term debt including current maturities
- 28.9 million USD Source
Exact value
28924000 USD
- Shares outstanding
- 28.8 million shares Source
Exact value
28821405 shares
Reported share-count change
2.19% · 617 thousand shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2019-11-12.
Financial data available through: 2018-12-31.
Coverage by financial measure
- Revenue: 2 of 11 periods available· newest 2018-12-31
- Operating income: 2 of 11 periods available· newest 2018-12-31
- Net income: 2 of 11 periods available· newest 2018-12-31
- Operating cash flow: 2 of 11 periods available· newest 2018-12-31
- Capital expenditure: 2 of 11 periods available· newest 2018-12-31
- Total assets: 2 of 11 periods available· newest 2018-12-31
- Total liabilities: 2 of 11 periods available· newest 2018-12-31
- Current assets: 2 of 11 periods available· newest 2018-12-31
- Current liabilities: 2 of 11 periods available· newest 2018-12-31
- Cash and cash equivalents: 2 of 11 periods available· newest 2018-12-31
- Long-term debt including current maturities: 2 of 11 periods available· newest 2018-12-31
- Shares outstanding: 2 of 11 periods available· newest 2018-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
+USD 10.36 millionPrior period
USD 0
–
Current period
USD 10.36 million
–
Exact inputs and evidence
10355000 − 0 = 10355000 USD
0 USD · 2017-01-01 – 2017-12-31
Inspect prior input Prior source10355000 USD · 2018-01-01 – 2018-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 42.33 millionPrior period
−USD 29.96 million
–
Current period
−USD 72.28 million
–
Exact inputs and evidence
-72282000 − -29955000 = -42327000 USD
-29955000 USD · 2017-01-01 – 2017-12-31
Inspect prior input Prior source-72282000 USD · 2018-01-01 – 2018-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 42.77 millionPrior period
−USD 10.9 million
–
Current period
−USD 53.67 million
–
Exact inputs and evidence
-53666000 − -10899000 = -42767000 USD
-10899000 USD · 2017-01-01 – 2017-12-31
Inspect prior input Prior source-53666000 USD · 2018-01-01 – 2018-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+491.9%Prior period
USD 62,000
–
Current period
USD 367,000
–
Exact inputs and evidence
367000 − 62000 = 305000 USD
62000 USD · 2017-01-01 – 2017-12-31
Inspect prior input Prior source367000 USD · 2018-01-01 – 2018-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2018 2018-01-01 – 2018-12-31
- Revenue USD 10.36 million 100% of revenue
- Operating costs Derived USD 81.41 million 786% of revenue
- Operating income −USD 71.05 million −686% of revenue
- Tax, interest and other Derived USD 1.23 million 12% of revenue
- Net income −USD 72.28 million −698% of revenue
Cash
- Operating cash flow −USD 53.67 million −518% of revenue
- Capital expenditure USD 367,000 3.5% of revenue
- Free cash flow Derived −USD 54.03 million −522% of revenue
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2017 Not shown: operating income or net income is not reported.
- 2018 Operating loss: operating costs were 786% of revenue.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2017 2017-01-01 – 2017-12-31 | 0 | 29209000 Derived | -29209000 | 746000 Derived | -29955000 | -10961000 Derived | Source
|
| 2018 2018-01-01 – 2018-12-31 | 10355000 | 81405000 Derived | -71050000 | 1232000 Derived | -72282000 | -54033000 Derived | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 10.4M 2018
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2017 | Revenue | 0 |
|
| 2018 | Revenue | 10355000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2017 | Year over year | No prior comparable period |
|
| 2018 | Year over year | No prior comparable period |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -686.1% 2018
Net margin -698% 2018
Free cash flow margin -521.8% 2018
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2017 | Operating margin | Not reported |
|
| 2018 | Operating margin | -686.1% |
|
| 2017 | Net margin | Not reported |
|
| 2018 | Net margin | -698% |
|
| 2017 | Free cash flow margin | Not reported |
|
| 2018 | Free cash flow margin | -521.8% |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -53.7M 2018
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2017 | Operating cash flow | -10899000 |
|
| 2018 | Operating cash flow | -53666000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
USD -54M 2018
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2017 | Free cash flow | -10961000 |
|
| 2018 | Free cash flow | -54033000 |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
31.9% 2018
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2017 | Liabilities / assets | 36.5% |
|
| 2018 | Liabilities / assets | 31.9% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
5.73× 2018
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2017 | Current assets / current liabilities | 2.74× |
|
| 2018 | Current assets / current liabilities | 5.73× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2017 2017-01-01 – 2017-12-31 | −USD 29.96 million Exact valueExact value: -29955000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 10.9 million Exact valueExact value: -10899000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 62,000 Exact valueExact value: 62000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 10.96 million Calculation and evidence-10899000 − 62000 USD Exact free cash flow: -10961000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2018 2018-01-01 – 2018-12-31 | −USD 72.28 million Exact valueExact value: -72282000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 53.67 million Exact valueExact value: -53666000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 367,000 Exact valueExact value: 367000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 54.03 million Calculation and evidence-53666000 − 367000 USD Exact free cash flow: -54033000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
13 filings · 915 latest values · 915 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001685071, 1685071, edgar:1685071
Also known as Dova Pharmaceuticals Inc., Dova Pharmaceuticals, Inc.